]>
IRCT2014030611375N2 IRCT 2014-04-09 Shiraz University of Midical Sciences Effects of walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients Effects of walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients 2013-10-10 anticipated 90 Complete https://irct.ir/trial/11639 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A Hyperlipidemia. Intervention 1: Intervention group will be administered with15cc Persian walnut (Juglans regia L.) oil, per day, for 90 days. Intervention 2: Control group will be received placebo (distilled water capsule) per day, for 90 days.
public Dr.pouya Farhadi
Cardiovascular Research Center, Shahid Faghihi Hospital, Zand ave.
Shiraz Iran (Islamic Republic of) +98 71 1234 3529 farhadip@sums.ac.ir Shiraz University of Medical Sciences scientific Dr. Mohammad Javad Zibaeenejhad
Cardiovascular Research Center, Shahid Faghihi Hospital, Zand ave.
Shiraz Iran (Islamic Republic of) +98 71 1234 3529 zibaeem2@sums.ac.ir Cardiovascular Research Center of Shiraz Iran (Islamic Republic of) Inclusion Criteria: Patients with diagnosed type2 diabetes for at leat 2 years and also with either plasma TG level more 150 mg/dL or total cholestrol level more 200 mg/dL or LDL between 130-200 or HDL less 50 in female and less 40 in male; Patients who received maximum 2 oral diabetes medications. Exclusion Criteria: Patients who have a history of chronic or metabolic diseases, or regularly use medication (Fibrate and HMG-COA Reductase inhibitor) or supplements known to affect blood lipids; Patients who have to receive antihyperlipidemic agents for example CAD patients; Patients who were currently received insulin therapy. 20 years 75 years Both E78 Disorders of lipoprotein metabolism and other lipidaemias Treatment - Drugs Placebo Intervention group will be administered with15cc Persian walnut (Juglans regia L.) oil, per day, for 90 days. Control group will be received placebo (distilled water capsule) per day, for 90 days. Serum Triglyceride. Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique). Low-density lipoprotein (LDL). Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique). High-density lipoprotein (HDL). Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (dextran magnesium sulfate). Total cholesterol. Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique). Body Mass Index. Timepoint: Before and 2 months after intervention. Method of measurement: By BMI Formula. Systolic Blood Pressure. Timepoint: Before and 3 months after intervention. Method of measurement: Mercury sphygmomanometer. Diastol Blood Pressure. Timepoint: Before and 3 months after intervention. Method of measurement: Mercury sphygmomanometer. Shiraz University of Midical Sciences Approved 2013-08-13 Shiraz University of Medical Sciences Shiraz university of medical sciences Building - 7th floor - Zand Ave. Shiraz Iran (Islamic Republic of)